Ouro Medicines

Acquired

Ouro Medicines is a biotech company in USA, United States, founded in 2025. It has raised $120.0M across 1 round, most recently a $120.0M Series A in January 2025.

Defining the future of treatment for people with immune-mediated diseases

Headquarters
USA, California
Employees
11–50
Founded
2025
Business Model
B2B
Total Funding
$120.0M
Last Round
$120.0M Series AJan 2025
Rounds
1
Acquisition Date
Mar 2026

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 8 investors for this company. The full record is or through the API.

About

Ouro Medicines is a clinical-stage biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases. Its lead program, OM336 (gamgertamig), is a BCMAxCD3 T cell engager in a basket study targeting multiple autoimmune conditions, and has received FDA Fast Track and Orphan Drug designations. In March 2026, Gilead Sciences announced an agreement to acquire Ouro for approximately $2.18 billion.

Summary

It lists 11–50 employees. It has raised $120.0M in total across 1 round, most recently a $120.0M Series A round in Jan 2025. Investors include New Enterprise Associates, TPG Life Sciences Innovation and Norwest Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionAcquisition by Gilead SciencesMar 2026

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ouro Medicines on Indexed.vc
<a href="https://indexed.vc/companies/ouro-medicines"><img src="https://indexed.vc/api/badge/company/ouro-medicines" alt="Ouro Medicines on Indexed.vc" width="260" height="76" /></a>